Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis

The kynurenine pathway (KP) is a major route of L-tryptophan catabolism leading to production of several neurobiologically active molecules. Among them is the excitotoxin quinolinic acid (QUIN) that is known to be involved in the pathogenesis of several major inflammatory neurological diseases. In amyotrophic lateral sclerosis (ALS) degeneration of motor neurons is associated with a chronic and local inflammation (presence of activated microglia and astrocytes). There is emerging evidence that the KP is important in ALS. Recently, we demonstrated that QUIN is significantly increased in serum and CSF of ALS patients. Moreover, most of the factors associated with QUIN toxicity are found in ALS, implying that QUIN may play a substantial role in the neuropathogenesis of ALS. This review details the potential role the KP has in ALS and advances a testable hypothetical model.

[1]  W. Bradley,et al.  Mitochondrial involvement in amyotrophic lateral sclerosis , 2007, Molecular Neurobiology.

[2]  V. Meininger Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans? , 2006, Neurodegenerative Diseases.

[3]  D. Walker,et al.  Quinolinic acid promotes albumin deposition in Purkinje cell, astrocytic activation and lipid peroxidation in fetal brain , 2005, Neuroscience.

[4]  P. Monk,et al.  Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis , 2005, Glia.

[5]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.

[6]  B. Brew,et al.  Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex , 2005, Journal of Neuroinflammation.

[7]  T. Möller,et al.  Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis , 2005, Neuroreport.

[8]  B. Brew,et al.  Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.

[9]  A. Cesura,et al.  Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators , 2005, Amino Acids.

[10]  I. Lapin,et al.  Excitatory effects of kynurenine and its metabolites, amino acids and convulsants administered into brain ventricles: Differences between rats and mice , 2005, Journal of Neural Transmission.

[11]  S. Appel,et al.  Sublethal dose of 4-hydroxynonenal reduces intracellular calcium in surviving motor neurons in vivo , 2005, Acta Neuropathologica.

[12]  J. Joseph,et al.  Mass spectral evidence for carbonate-anion-radical-induced posttranslational modification of tryptophan to kynurenine in human Cu, Zn superoxide dismutase. , 2004, Free radical biology & medicine.

[13]  J. Reinhard Pharmacological Manipulation of Brain Kynurenine Metabolism , 2004, Annals of the New York Academy of Sciences.

[14]  L. Barbeito,et al.  A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis , 2004, Brain Research Reviews.

[15]  T. Gillingwater,et al.  A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. , 2004, American journal of human genetics.

[16]  W. Le,et al.  Activated Microglia Initiate Motor Neuron Injury by a Nitric Oxide and Glutamate‐Mediated Mechanism , 2004, Journal of neuropathology and experimental neurology.

[17]  J. Loeffler,et al.  Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Shibasaki,et al.  Effects of mitochondrial dysfunction on glutamate receptor-mediated neurotoxicity in cultured rat spinal motor neurons , 2004, Brain Research.

[19]  Deanna L. Taylor,et al.  Microglia release activators of neuronal proliferation mediated by activation of mitogen‐activated protein kinase, phosphatidylinositol‐3‐kinase/Akt and delta–Notch signalling cascades , 2004, Journal of neurochemistry.

[20]  L. Bruijn,et al.  Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.

[21]  S. Paredes,et al.  Orally administered tryptophan and experimental type 2 diabetes , 2004, Molecular and Cellular Biochemistry.

[22]  U. Kumar Characterization of striatal cultures with the effect of QUIN and NMDA , 2004, Neuroscience Research.

[23]  A. Chakrabartty,et al.  Monomeric Cu,Zn-superoxide Dismutase Is a Common Misfolding Intermediate in the Oxidation Models of Sporadic and Familial Amyotrophic Lateral Sclerosis*[boxs] , 2004, Journal of Biological Chemistry.

[24]  L. Barbeito,et al.  Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis , 2004, Journal of neurochemistry.

[25]  Colin L. Masters,et al.  Neurodegenerative diseases and oxidative stress , 2004, Nature Reviews Drug Discovery.

[26]  M. E. Frizzo,et al.  Riluzole Enhances Glutamate Uptake in Rat Astrocyte Cultures , 2004, Cellular and Molecular Neurobiology.

[27]  T. Siddique,et al.  Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue , 2004, Annals of neurology.

[28]  S. Przedborski Programmed Cell Death in Amyotrophic Lateral Sclerosis: a Mechanism of Pathogenic and Therapeutic Importance , 2004, The neurologist.

[29]  H. Vinters,et al.  Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[30]  A. Santamaría,et al.  Quinolinic acid is a potent lipid peroxidant in rat brain homogenates , 1991, Neurochemical Research.

[31]  I. Niebroj-Dobosz,et al.  Oxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis (ALS). , 2004, Folia neuropathologica.

[32]  G. Deuschl,et al.  Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration , 2003, Journal of Neuroimmunology.

[33]  Scott Ferrell,et al.  Message and protein-level elevation of tumor necrosis factor α (TNFα) and TNFα-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis , 2003, Neurobiology of Disease.

[34]  M. Strong,et al.  Amyotrophic lateral sclerosis: A review of current concepts , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[35]  J. Moffett,et al.  Tryptophan and the immune response , 2003, Immunology and cell biology.

[36]  K. Žarković 4-hydroxynonenal and neurodegenerative diseases. , 2003, Molecular aspects of medicine.

[37]  J. Joseph,et al.  Bicarbonate-dependent Peroxidase Activity of Human Cu,Zn-Superoxide Dismutase Induces Covalent Aggregation of Protein , 2003, Journal of Biological Chemistry.

[38]  W. Turski,et al.  Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis , 2003, Acta neurologica Scandinavica.

[39]  B. Brew,et al.  Expression of chemokines and their receptors in human and simian astrocytes: Evidence for a central role of TNFα and IFNγ in CXCR4 and CCR5 modulation , 2003 .

[40]  B. Brew,et al.  Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes , 2003, Glia.

[41]  I. Regidor,et al.  Low concentrations of glutamate induce apoptosis in cultured neurons: Implications for amyotrophic lateral sclerosis , 2003, Journal of the Neurological Sciences.

[42]  S. Appel,et al.  PARP Expression Is Increased in Astrocytes but Decreased in Motor Neurons in the Spinal Cord of Sporadic ALS Patients , 2003, Journal of neuropathology and experimental neurology.

[43]  B. Brew,et al.  Quinolinic acid in the pathogenesis of Alzheimer's disease. , 2003, Advances in experimental medicine and biology.

[44]  B. Brew,et al.  Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.

[45]  W. Streit Microglia as neuroprotective, immunocompetent cells of the CNS , 2002, Glia.

[46]  P. Mcgeer,et al.  Inflammatory processes in amyotrophic lateral sclerosis , 2002, Muscle & nerve.

[47]  P. Heath,et al.  Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis , 2002, Muscle & nerve.

[48]  K. Ikeda,et al.  Molecular and cellular mechanism of glutamate receptors in relation to amyotrophic lateral sclerosis. , 2002, Current drug targets. CNS and neurological disorders.

[49]  P. Riederer,et al.  Degeneration of neuronal cells due to oxidative stress--microglial contribution. , 2002, Parkinsonism & related disorders.

[50]  M. Strong,et al.  Activated microglia (BV-2) facilitation of TNF-α-mediated motor neuron death in vitro , 2002, Journal of Neuroimmunology.

[51]  A. Nagai,et al.  Cytokines, chemokines, and cytokine receptors in human microglia , 2002, Journal of neuroscience research.

[52]  K. Fischbeck,et al.  Toxic Proteins in Neurodegenerative Disease , 2002, Science.

[53]  D. Souza,et al.  Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes , 2002, Neurochemistry International.

[54]  P. Smyth,et al.  Markers of apoptosis: methods for elucidating the mechanism of apoptotic cell death from the nervous system. , 2002, BioTechniques.

[55]  V. Meininger,et al.  Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients , 2002, Journal of the Neurological Sciences.

[56]  B Balachandran,et al.  Role of Oxidative Stress and Antioxidants in Neurodegenerative Diseases , 2002, Nutritional neuroscience.

[57]  K. Hensley,et al.  Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. , 2002, Journal of neurochemistry.

[58]  D. Price,et al.  Histological Evidence of Protein Aggregation in Mutant SOD1 Transgenic Mice and in Amyotrophic Lateral Sclerosis Neural Tissues , 2001, Neurobiology of Disease.

[59]  S Cluskey,et al.  Mechanisms of neurodegeneration in amyotrophic lateral sclerosis , 2001, Molecular pathology : MP.

[60]  B. Sela [Role of caspases in neural degeneration in amyotrophic lateral sclerosis]. , 2001, Harefuah.

[61]  N. Shibata,et al.  Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients , 2001, Brain Research.

[62]  V. Silani,et al.  Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity , 2001, Journal of the Neurological Sciences.

[63]  S. Appel,et al.  Immune reactivity in a mouse model of familial ALS correlates with disease progression , 2001, Neurology.

[64]  M. Swash,et al.  Amyotrophic Lateral Sclerosis: Current Understanding , 2001, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[65]  A. Camacho,et al.  In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum , 2001, Neuroreport.

[66]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.

[67]  P. Ince,et al.  Apoptosis in amyotrophic lateral sclerosis: a review of the evidence , 2001, Neuropathology and applied neurobiology.

[68]  A. Santamaría,et al.  Quinolinic acid induces oxidative stress in rat brain synaptosomes , 2001, Neuroreport.

[69]  T. Stone,et al.  Endogenous neurotoxins from tryptophan. , 2001, Toxicon : official journal of the International Society on Toxinology.

[70]  M. Sanjak,et al.  Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[71]  M. Müller,et al.  Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. , 2000, The Biochemical journal.

[72]  J. Urenjak,et al.  NEUROPHARMACOLOGY: Neuroprotective potency of kynurenic acid against excitotoxicity , 2022 .

[73]  D. Souza,et al.  Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain , 2000, Neuroreport.

[74]  W. Behan,et al.  Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species , 2000, Amino Acids.

[75]  T. Stone,et al.  Oxidative stress as a mechanism for quinolinic acid‐induced hippocampal damage: protection by melatonin and deprenyl , 1999, British journal of pharmacology.

[76]  R. Schwarcz,et al.  3‐Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum , 1999, The European journal of neuroscience.

[77]  D. Schiffer,et al.  Lack of apoptosis in mice with ALS , 1999, Nature Medicine.

[78]  F. Moroni,et al.  Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. , 1999, European journal of pharmacology.

[79]  E. Fedele,et al.  Intracerebral administration of l-kynurenine decreases N-methyl-d-aspartate receptor-mediated production of cGMP in the cerebellum and hippocampus of unanaesthetized rats subjected to transcerebral microdialysis , 1999, Neuroscience Letters.

[80]  F. Moroni,et al.  Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. , 1999, Advances in experimental medicine and biology.

[81]  R. Stocker,et al.  Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. , 1999, Redox report : communications in free radical research.

[82]  M. Mattson,et al.  Presence of 4‐hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis , 1998, Annals of neurology.

[83]  L. Bruijn,et al.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. , 1998, Science.

[84]  Marco Di Benedetto,et al.  Solution structure of reduced monomeric Q133M2 copper, zinc superoxide dismutase (SOD). Why is SOD a dimeric enzyme?. , 1998, Biochemistry.

[85]  G. Wolf,et al.  Differential expression of superoxide dismutase isoforms in neuronal and glial compartments in the course of excitotoxically mediated neurodegeneration: Relation to oxidative and nitrergic stress , 1998, Glia.

[86]  A. Berger Amyloid clearly implicated in Alzheimer's disease , 1998 .

[87]  M. Gurney,et al.  Relationship of oxygen radical‐induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS , 1998, Journal of neuroscience research.

[88]  Bruce A. Yankner,et al.  Aging renders the brain vulnerable to amyloid β-protein neurotoxicity , 1998, Nature Medicine.

[89]  M. Sawada,et al.  Tryptophan and its metabolite, kynurenine, stimulate expression of nerve growth factor in cultured mouse astroglial cells , 1998, Neuroscience Letters.

[90]  B. Brew,et al.  Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex , 1998, AIDS.

[91]  B. Crain,et al.  Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. , 1998, American journal of human genetics.

[92]  G. Levi,et al.  Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide , 1998, Progress in Neurobiology.

[93]  A. Santamaría,et al.  Effects of Nω-nitro-L-arginine and L-arginine on quinolinic acid-induced lipid peroxidation , 1997 .

[94]  D. Troost,et al.  c‐Jun, JNK/SAPK Kinase and Transcription Factor NF-κB Are Selectively Activated in Astrocytes, but not Motor Neurons, in Amyotrophic Lateral Sclerosis , 1997, Journal of neuropathology and experimental neurology.

[95]  S. Furukawa,et al.  Stimulation of NGF production by tryptophan and its metabolites in cultured mouse astroglial cells. , 1997, Brain research.

[96]  B. Brew,et al.  Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α , 1997 .

[97]  Dennis P. Nelson,et al.  Energetic Dysfunction in Quinolinic Acid‐Lesioned Rat Striatum , 1997, Journal of neurochemistry.

[98]  K. Kawai,et al.  Species Heterogeneity Between Gerbils and Rats: Quinolinate Production by Microglia and Astrocytes and Accumulations in Response to Ischemic Brain Injury and Systemic Immune Activation , 1997, Journal of neurochemistry.

[99]  Hassan Mohammad Naif,et al.  HIV infection of macrophages and pathogenesis of AIDS dementia complex: interaction of the host cell and viral genotype , 1997, Journal of leukocyte biology.

[100]  C. Colton,et al.  Activated human microglia produce the excitotoxin quinolinic acid , 1997, Neuroreport.

[101]  B. Brew,et al.  Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[102]  R. Stocker,et al.  3-Hydroxyanthranilic Acid Is an Efficient, Cell-derived Co-antioxidant for α-Tocopherol, Inhibiting Human Low Density Lipoprotein and Plasma Lipid Peroxidation* , 1996, The Journal of Biological Chemistry.

[103]  R. Burke,et al.  Apoptotic neuron death in rat substantia nigra induced by striatal excitotoxic injury is developmentally dependent , 1996, Neuroscience Letters.

[104]  H. Saito,et al.  3-Hydroxykynurenine toxicity on the rat striatum in vivo. , 1996, Japanese journal of pharmacology.

[105]  S. Samarasinghe,et al.  Distribution of the N-methyl-d-aspartate glutamate receptor subunit NR2A in control and amyotrophic lateral sclerosis spinal cord , 1996, Brain Research.

[106]  C. Colton,et al.  Species differences in the generation of reactive oxygen species by microglia , 1996, Molecular and chemical neuropathology.

[107]  P. Ricciardi-Castagnoli,et al.  Regulation of the Kynurenine Metabolic Pathway by Interferon‐γ in Murine Cloned Macrophages and Microglial Cells , 1996, Journal of neurochemistry.

[108]  E. Major,et al.  Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. , 1992, The Biochemical journal.

[109]  K. Goda,et al.  Quinolinic Acid and Active Oxygens , 1996 .

[110]  M. Heyes The Kynurenine Pathway and Neurologic Disease , 1996 .

[111]  G. Melillo,et al.  Immunobiology of picolinic acid. , 1996, Advances in experimental medicine and biology.

[112]  M. Heyes The kynurenine pathway and neurologic disease. Therapeutic strategies. , 1996, Advances in experimental medicine and biology.

[113]  K. Goda,et al.  Quinolinic acid and active oxygens. Possible contribution of active Oxygens during cell death in the brain. , 1996, Advances in experimental medicine and biology.

[114]  G. Curzon Brain tryptophan. Normal and disturbed control. , 1996, Advances in experimental medicine and biology.

[115]  N. Botting Chemistry and neurochemistry of the kynurenine pathway of tryptophan metabolism , 1996 .

[116]  J Kerby,et al.  Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. , 1995, Molecular pharmacology.

[117]  M. Rosenblum,et al.  AIDS dementia complex and HIV‐1 brain infection: Clinical‐virological correlations , 1995, Annals of neurology.

[118]  R. Banati,et al.  Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. , 1995, Clinical Neuropathology.

[119]  G. Kreutzberg,et al.  Microglia, the first line of defence in brain pathologies. , 1995, Arzneimittel-Forschung.

[120]  J. Rothstein Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. , 1995, Clinical neuroscience.

[121]  B. Brew,et al.  Neurocytotoxity of quinolinic acid in human brain cultures. , 1995, Journal of neurovirology.

[122]  R. Burke,et al.  Apoptosis in substantia nigra following developmental striatal excitotoxic injury. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[123]  K. Kristensson,et al.  Co-induction of neuronal interferon-gamma and nitric oxide synthase in rat motor neurons after axotomy: a role in nerve repair or death? , 1994, Journal of neurocytology.

[124]  J. Haines,et al.  Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33–q35 , 1994, Nature Genetics.

[125]  R. Stocker,et al.  Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. , 1994, The Journal of biological chemistry.

[126]  D. Longo,et al.  Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. , 1994, Blood.

[127]  D. Troost,et al.  Neuronophagia in the motor cortex in amyotrophic lateral sclerosis , 1993, Neuropathology and applied neurobiology.

[128]  T. Stone,et al.  Neuropharmacology of quinolinic and kynurenic acids. , 1993, Pharmacological reviews.

[129]  A. Schurr,et al.  Quinolinate potentiates the neurotoxicity of excitatory amino acids in hypoxic neuronal tissue in vitro , 1993, Brain Research.

[130]  M. Heyes Metabolism and neuropathologic significance of quinolinic acid and kynurenic acid. , 1993, Biochemical Society transactions.

[131]  P. Sindou,et al.  Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors , 1993, The Lancet.

[132]  M. Demitrack,et al.  Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.

[133]  P. Mcgeer,et al.  Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. , 1992, The American journal of pathology.

[134]  S. Markey,et al.  Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. , 1992, The Biochemical journal.

[135]  G. Martin,et al.  Glutamine synthesis from aspartate in guinea-pig renal cortex. , 1990, The Biochemical journal.

[136]  K. Kristensson,et al.  Gamma-interferon-like immunoreactivity in axotomized rat motor neurons , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[137]  T. Guilarte,et al.  Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line , 1989, Brain Research.

[138]  R. Beninger,et al.  Kynurenic acid protects against the neurochemical and behavioral effects of unilateral quinolinic acid injections into the nucleus basalis of rats. , 1989, Behavioral neuroscience.

[139]  R. Schwarcz,et al.  Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid , 1984, Neuroscience Letters.

[140]  R. Schwarcz,et al.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.

[141]  D. Bender,et al.  The preferred route of kynurenine metabolism in the rat. , 1982, Biochimica et biophysica acta.

[142]  T. Stone,et al.  Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. , 1981, European journal of pharmacology.